$2.02
+0.00 (+0.00%)
Open$2.01
Previous Close$2.02
Day High$2.07
Day Low$2.00
52W High$5.96
52W Low$2.00
Volume—
Avg Volume10.7K
Market Cap21.79M
P/E Ratio—
EPS$-2.89
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,003.0% upside
Current
$2.02
$2.02
Target
$42.48
$42.48
$23.35
$42.48 avg
$52.53
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 671.1K | 1.18M | 4.21M |
| Net Income | -38,450,706 | -17,884,542 | -76,163 |
| Profit Margin | -6,407.4% | -1,605.8% | -1.8% |
| EBITDA | -37,219,619 | -17,808,595 | -73,642 |
| Free Cash Flow | — | — | -41,548 |
| Rev Growth | +131.9% | +78.7% | +17.4% |
| Debt/Equity | 250.28 | 250.29 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |